You are here: Industry Insights > Lonza

News List

Lonza Expands HPAPI Capabilities contractpharma
November 20, 2020
Lonza has made additional investments in its oral drug product development and manufacturing capabilities at its Tampa, FL site. Capability for formulation development has been enhanced with the upgrade of drug product development laboratories for ...
Ypsomed, SCHOTT Collaborate with Lonza to Develop Patch Injector Solution americanpharmaceuticalreview
November 20, 2020
Ypsomed is advancing its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT and Lonza. In a joint effort, the three companies are developing a solution for wearable patch injectors for the subcutaneous ...
Lonza has made additional investments in its oral drug product development and manufacturing capabilities at its Tampa, FL site. Capability for formulation development has been enhanced with the upgra contractpharma
November 19, 2020
Lonza has made additional investments in its oral drug product development and manufacturing capabilities at its Tampa, FL site. Capability for formulation development has been enhanced with the upgrade of drug product development laboratories for ...
Fujifilm Cellular Dynamics and Lonza Enter Cell Therapy Partnership contractpharma
November 17, 2020
Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc., a leading global GMP iPSC manufacturer, have entered into a partnership.
Altimmune Adds Lonza as Mfg. Partner for Supply of AdCOVID contractpharma
November 12, 2020
Single-dose intranasal vaccine for COVID-19 designed to generate a broad immune response with nasal mucosal immunity to prevent infection and transmission.
Ypsomed Collaborates with Schott and Lonza contractpharma
November 11, 2020
Ypsomed has entered into a collaboration with Schott and Lonza to be able to offer the YpsoDose patch injector platform, which is used for the subcutaneous self-administration of high volumes of pharmaceuticals, as a fully integrated solution.
Lonza Opens Facility for ADC Payload Manufacturing contractpharma
November 06, 2020
Lonza, a specialty CDMO partner to the biopharma industry, has inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp, Switzerland site.
Lonza Appoints CEO contractpharma
November 04, 2020
Lonza Group has appointed Pierre-Alain Ruffieux to the role of Chief Executive Officer. Albert Baehny has served in the role on an interim basis since November 2019.
Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination contractpharma
November 02, 2020
cGMP manufacturing of the two long-acting antibodies to begin in H1 2021 at Lonza's Portsmouth, NH (USA) site.
Lonza Expands Capsule Manufacturing Capacity americanpharmaceuticalreview
October 29, 2020
Lonza announced a CHF85m ($93m) investment in its Capsules and Health Ingredients (CHI) Division, a dosage form delivery partner to the biopharma and health nutrition industry.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page